Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash & Equivalents: 2012-2024

Historic Cash & Equivalents for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $392.1 million.

  • Ocular Therapeutix's Cash & Equivalents fell 19.30% to $344.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.8 million, marking a year-over-year decrease of 19.30%. This contributed to the annual value of $392.1 million for FY2024, which is 100.25% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Cash & Equivalents of $392.1 million as of FY2024, which was up 100.25% from $195.8 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Cash & Equivalents peaked at $392.1 million during FY2024, and registered a low of $102.3 million during FY2022.
  • For the 3-year period, Ocular Therapeutix's Cash & Equivalents averaged around $230.1 million, with its median value being $195.8 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 318.94% in 2020, then slumped by 37.68% in 2022.
  • Over the past 5 years, Ocular Therapeutix's Cash & Equivalents (Yearly) stood at $228.1 million in 2020, then fell by 28.02% to $164.2 million in 2021, then crashed by 37.68% to $102.3 million in 2022, then surged by 91.40% to $195.8 million in 2023, then surged by 100.25% to $392.1 million in 2024.